Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Even, Aniek J.G., Hamming-Vrieze, Olga, van Elmpt, Wouter, Winnepenninckx, Véronique J.L., Heukelom, Jolien, Tesselaar, Margot E.T., Vogel, Wouter V., Hoeben, Ann, Zegers, Catharina M.L., Vugts, Daniëlle J., van Dongen, Guus A.M.S., Bartelink, Harry, Mottaghy, Felix M., Hoebers, Frank, Lambin, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354801/
https://ncbi.nlm.nih.gov/pubmed/27965472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados